GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Leap Therapeutics Inc (FRA:5MC) » Definitions » Sale Of Business

Leap Therapeutics (FRA:5MC) Sale Of Business : €0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Leap Therapeutics Sale Of Business?

Leap Therapeutics's sale of business for the three months ended in Dec. 2024 was €0.00 Mil. It means Leap Therapeutics gained €0.00 Mil from selling business. Leap Therapeutics's sale of business for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Sep. 2024 ), Leap Therapeutics gained the same money from selling business in Dec. 2024 (€0.00 Mil).


Leap Therapeutics Sale Of Business Historical Data

The historical data trend for Leap Therapeutics's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Leap Therapeutics Sale Of Business Chart

Leap Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Sale Of Business
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 46.18 -

Leap Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Sale Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Leap Therapeutics Sale Of Business Calculation

The amount earned to sell business.


Sale Of Business for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Leap Therapeutics Sale Of Business Related Terms

Thank you for viewing the detailed overview of Leap Therapeutics's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


Leap Therapeutics Business Description

Traded in Other Exchanges
Address
47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

Leap Therapeutics Headlines

No Headlines